Hirotake Tsukamoto

Profile Information

Affiliation: Junior Associate Professor, Center for Cancer Immunotherapy and Immunobiology, Kyoto University

Degree: Ph.D(Kumamoto University)

Other name(s) (e.g. nickname): Tsukamoto Hirotake
J-GLOBAL ID: 200901052479621533
researchmap Member ID: 5000094018

Research Interests

Research Areas

Life sciences / Immunology /

Research History

Apr, 2016 - Mar, 2021

Department of Immunology, Graduate School of Medical Sciences, Kumamoto University
2010

Faculty of Life Sciences, Kumamoto University
2010

Assistant Professor,Faculty of Life Sciences(Basic medicine group),Kumamoto University

Education

Apr, 2002 - Mar, 2006

Kumamoto University
Apr, 2000 - Mar, 2002

Kumamoto University
Apr, 1996 - Mar, 2000

Tottori University

Committee Memberships

2015 - Present

評議員, 日本がん免疫学会

Awards

Dec, 2018

Best Presentation Award, Japanese Society of Immunology

Tsukamoto Hirotake
Nov, 2016

Research Achievement Award

Hirotake Tsukamoto
2013

Young Investigator Award

Hirotake Tsukamoto
2013

Tadamitsu Kishimoto International Travel Award

Papers

Association of Clostridium butyricum Therapy Using the Live Bacterial Product CBM588 with the Survival of Patients with Lung Cancer Receiving Chemoimmunotherapy Combinations

Yusuke Tomita, Shinya Sakata, Kosuke Imamura, Shinji Iyama, Takayuki Jodai, Koichi Saruwatari, Shohei Hamada, Kimitaka Akaike, Moriyasu Anai, Kazuaki Fukusima …

Cancers, 16(1) 47-47, Dec 21, 2023
Predictive value of CXCL10 for the occurrence of immune-related adverse events in patient with renal cell carcinoma.

Yuji Miura, Takanobu Motoshima, Toshiki Anami, Hiromu Yano, Remi Mito, Cheng Pan, Shinji Urakami, Keiichi Kinowaki, Hirotake Tsukamoto, Ryoma Kurahashi …

Microbiology and immunology, Mar 28, 2023
Involvement of protumor macrophages in breast cancer progression and characterization of macrophage phenotypes.

Yoshihiro Komohara, Daisuke Kurotaki, Hirotake Tsukamoto, Yuko Miyasato, Hiromu Yano, Cheng Pan, Yutaka Yamamoto, Yukio Fujiwara

Cancer science, Feb 7, 2023
Stromal reprogramming through dual PDGFRα/β blockade boosts the efficacy of anti-PD-1 immunotherapy in fibrotic tumors.

Takahiko Akiyama, Tadahito Yasuda, Tomoyuki Uchihara, Noriko Yasuda-Yoshihara, Benjy J Y Tan, Atsuko Yonemura, Takashi Semba, Juntaro Yamasaki, Yoshihiro Komohara, Koji Ohnishi …

Cancer research, 83(5) 753-770, Dec 21, 2022
Aging-associated and CD4 T-cell–dependent ectopic CXCL13 activation predisposes to anti–PD-1 therapy-induced adverse events

Hirotake Tsukamoto, Yoshihiro Komohara, Yusuke Tomita, Yuji Miura, Takanobu Motoshima, Kosuke Imamura, Toshiki Kimura, Tokunori Ikeda, Yukio Fujiwara, Hiromu Yano …

Proceedings of the National Academy of Sciences, 119(29), Jul 19, 2022 Peer-reviewedLead authorCorresponding author
E3 Ubiquitin Ligase Riplet Is Expressed in T Cells and Suppresses T Cell-Mediated Antitumor Immune Responses.

Asuka Iwamoto, Hirotake Tsukamoto, Hideki Nakayama, Hiroyuki Oshiumi

Journal of immunology (Baltimore, Md. : 1950), 208(8) 2067-2076, Apr 15, 2022 Peer-reviewedCorresponding author
Circulating extracellular vesicle microRNAs associated with adverse reactions, proinflammatory cytokine, and antibody production after COVID-19 vaccination.

Yusuke Miyashita, Takanobu Yoshida, Yuriko Takagi, Hirotake Tsukamoto, Ken Takashima, Takahisa Kouwaki, Katsunari Makino, Satoshi Fukushima, Kimitoshi Nakamura, Hiroyuki Oshiumi

NPJ vaccines, 7(1) 16-16, Feb 8, 2022 Peer-reviewed
TICAM-1/TRIF associates with Act1 and suppresses IL-17 receptor-mediated inflammatory responses.

Yusuke Miyashita, Takahisa Kouwaki, Hirotake Tsukamoto, Masaaki Okamoto, Kimitoshi Nakamura, Hiroyuki Oshiumi

Life science alliance, 5(2), Feb, 2022 Peer-reviewedCorresponding author
β-glucan from Aureobasidium pullulans augments the anti-tumor immune responses through activated tumor-associated dendritic cells.

Yifang Shui, Xin Hu, Hiroshi Hirano, Kisato Kusano, Hirotake Tsukamoto, Mengquan Li, Kenichiro Hasumi, Wen-Zhi Guo, Xiao-Kang Li

International immunopharmacology, 101(Pt A) 108265-108265, Dec, 2021 Peer-reviewed
Improved safety of induced pluripotent stem cell-derived antigen presenting cell-based cancer immunotherapy.

Mashima H, Zhang R, Kobayashi T, Hagiya Y, Tsukamoto H, Liu T, Iwama T, Nakatsuka R, Mishima Y, Okada S …

Mol. Ther. Methods Clin. Dev., Apr, 2021 Peer-reviewed
Immunotherapy with 4-1BBL-Expressing iPS Cell‐Derived Myeloid Lines Amplifies Antigen-Specific T Cell Infiltration in Advanced Melanoma

Haruka Kuriyama, Satoshi Fukushima, Toshihiro Kimura, Hisashi Kanemaru, Azusa Miyashita, Etsuko Okada, Yosuke Kubo, Satoshi Nakahara, Aki Tokuzumi, Yuki Nishimura …

International Journal of Molecular Sciences, 22(4) 1958-1958, Feb 16, 2021 Peer-reviewed
miR-451a levels rather than human papillomavirus vaccine administration is associated with the severity of murine experimental autoimmune encephalomyelitis.

Nakashima M, Ishikawa K, Fugiwara A, Shu K, Fukushima Y, Okamoto M, Tsukamoto H, Kouwaki T, Oshiumi H

Scientific Reports, 11(1) 9369-9369, 2021 Peer-reviewed
The role of macrophages in anti-tumor immune responses: pathological significance and potential as therapeutic targets

Tsukamoto H, Komohara Y, Oshiumi H

Human Cell, 34(4) 1031-1039, 2021 Peer-reviewedLead author
悪性黒色腫に対するiPS細胞由来OX40L導入マクロファージ療法の開発

木村俊寛, 福島聡, 岡田悦子, 栗山春香, 金丸央, 久保陽介, 中原智史, 宮下梓, 塚本博丈, 西村泰治 …

日本がん免疫学会総会プログラム・抄録集, 24回 118-118, Sep, 2020
Aging-Associated Extracellular Vesicles Contain Immune Regulatory microRNAs Alleviating Hyperinflammatory State and Immune Dysfunction in the Elderly.

Hirotake Tsukamoto, Takahisa Kouwaki, Hiroyuki Oshiumi

iScience, 23(9) 101520-101520, Sep 1, 2020 Peer-reviewedLead authorCorresponding author
Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response

Mashima H, Zhang R, Kobayashi T, Hagiya Y, Tsukamoto H, Liu T, Iwama T, Nakatsuka R, Mishima Y, Okada S …

OncoImmunology, 9(1) 1814620-1814620, Sep, 2020 Peer-reviewed
HTLV-1 induces T cell malignancy and inflammation by viral antisense factor-mediated modulation of the cytokine signaling.

Yusuke Higuchi, Jun-Ichirou Yasunaga, Yu Mitagami, Hirotake Tsukamoto, Kazutaka Nakashima, Koichi Ohshima, Masao Matsuoka

Proceedings of the National Academy of Sciences of the United States of America, 117(24) 13740-13749, May 29, 2020 Peer-reviewed
Induced pluripotent stem cell-derived myeloid cells expressing OX40 ligand amplify antigen-specific T cells in advanced melanoma.

Toshihiro Kimura, Satoshi Fukushima, Etsuko Okada, Haruka Kuriyama, Hisashi Kanemaru, Mina Kadohisa-Tsuruta, Yosuke Kubo, Satoshi Nakahara, Aki Tokuzumi, Ikko Kajihara …

Pigment cell & melanoma research, 33(5) 744-755, Apr 30, 2020 Peer-reviewed
Cancer therapy with major histocompatibility complex-deficient and interferon β-producing myeloid cells derived from allogeneic embryonic stem cells.

Satoshi Umemoto, Miwa Haruta, Masataka Sakisaka, Tokunori Ikeda, Hirotake Tsukamoto, Yoshihiro Komohara, Motohiro Takeya, Yasuharu Nishimura, Satoru Senju

Cancer science, 110(10) 3027-3037, Oct, 2019 Peer-reviewed
【がん免疫療法の個別化を支える新・腫瘍免疫学】第I部腫瘍免疫応答の基本とその制御メカニズム (第1章)腫瘍免疫応答の正負の調節機構がん免疫におけるマクロファージの役割病態形成における存在意義と標的細胞としての可能性

菰原義弘, 塚本博丈

実験医学, 37(15) 2443-2451, Sep, 2019

Books and Other Publications

Precision Medicine "Development of combined cancer immunotherapy based on age-associated immune dysfunction"

Hirotake Tsukamoto

Dec, 2020
The role of macrophages in anti-tumor immune response

Yoshihiro Komohara, Hirotake Tsukamoto (Role: Joint author)

Yodosha, Sep, 2019
「IL-6とPD-1/PD-L1シグナルの併用阻害による免疫抑制効果の相互制御の遮断」臨床免疫・アレルギー科

塚本博丈

科学評論社, Aug, 2019
「免疫老化とがん免疫」アンチ・エイジング医学

塚本博丈

メディカルレビュー社, 2017
「IL-6と老年における免疫応答の低下」臨床免疫・アレルギー科, 科学評論社

塚本博丈

科学評論社, 2016
「Myeloid-derived suppressor cells (MDSC)によるTh1細胞の抑制機序」臨床免疫・アレルギー科

塚本博丈

科学評論社, 2014
「腫瘍免疫の最前線： T細胞を介した抗腫瘍免疫応答」実験医学9月増刊

塚本博丈, 西村泰治 (Role: Joint author)

羊土社, Sep, 2013
炎症・免疫分野のノーベル賞炎症と免疫

塚本博丈, 西村靖治 (Role: Joint author)

先端医学社, 2010
抗原認識のメカニズム Medicina

塚本博丈, 西村靖治 (Role: Joint author)

医学書院, 2006
MHCによる抗原提示バイオ研究マスターシリーズ免疫学集中マスター

塚本博丈, 西村靖治 (Role: Joint author)

羊土社, 2005
CLIP置換型インバリアント鎖遺伝子を利用したペプチド/MHC-II複合体発現細胞システムの構築 Medical Science Digest

塚本博丈, 西村靖治 (Role: Joint author)

ニューサイエンス社, 2005

Misc.

【がん免疫療法の個別化を支える新・腫瘍免疫学】第I部腫瘍免疫応答の基本とその制御メカニズム (第1章)腫瘍免疫応答の正負の調節機構がん免疫におけるマクロファージの役割病態形成における存在意義と標的細胞としての可能性

菰原義弘, 塚本博丈

実験医学, 37(15) 2443-2451, Sep, 2019
【がん免疫と免疫療法】IL-6とPD-1/PD-L1シグナルの併用阻害による免疫抑制効果の相互制御の遮断

塚本博丈, 押海裕之

臨床免疫・アレルギー科, 72(2) 165-173, Aug, 2019
悪性黒色腫に対する4-1BBリガンド導入iPS細胞由来ミエロイドラインを用いた免疫療法

栗山春香, 福島聡, 木村俊寛, 石橋卓行, 門久美菜, 久保陽介, 中原智史, 宮下梓, 猪爪隆史, 塚本博丈 …

日本がん免疫学会総会プログラム・抄録集, 23回 110-110, Jul, 2019
Combination of anti-IL-6 and anti-PD-L1 antibodies synergistically reinvigorates cancer immunity by activating both CTL and Th1 cells in mice

Yasuharu Nishimura, Koji Fujieda, Azusa Miyashita, Satoshi Fukushima, Tokunori Ikeda, Yosuke Kubo, Satoru Senju, Hironobu Ihn, Hiroyuki Oshiumi, Hirotake Tsukamoto

CANCER RESEARCH, 79(13), Jul, 2019
Combined blockade of IL-6 and PD-1/PD-L1 signals breaks mutual regulation of their immunosuppressive effects

Hirotake Tsukamoto, Koji Fujieda, Azusa Miyashita, Satoshi Fukushima, Tokunori Ikeda, Yosuke Kubo, Satoru Senju, Hironobu Ihn, Yasuharu Nishimura, Hiroyuki Oshiumi

CANCER SCIENCE, 109 624-624, Dec, 2018
Immunosuppressive effects of IL-6/sIL-6R on Th1-cell-mediated anti-tumor immunity in tumor-bearing mice and patients(和訳中)

西村泰治, 藤枝浩司, 千住覚, 平山正敏, 福間大喜, 宮下梓, 福島聡, 池田徳典, 尹浩信, 中山秀樹 …

日本がん免疫学会総会プログラム・抄録集, 22回 105-105, Jul, 2018
MHC欠損ES細胞由来IFN産生ミエロイド細胞による大腸癌転移モデルのアロ個体への治療効果と宿主免疫系に及ぼす影響

梅本覚司, 春田美和, 匂坂正孝, 粟井博丈, 池田徳典, 竹屋元裕, 菰原義弘, 西村泰治, 千住覚

日本がん免疫学会総会プログラム・抄録集, 22回 147-147, Jul, 2018
Nivolumabによる大腸炎を発症した患者における免疫学的解析

宮下梓, 福島聡, 塚本博丈, 板井久恵, 藤枝浩司, 西村泰治, 宮本英明, 尹浩信

日本がん免疫学会総会プログラム・抄録集, 21回 143-143, Jun, 2017
免疫抑制因子としてのIL‐6シグナルを標的とした抗腫瘍免疫応答予測と,IL‐6/PD‐L1阻害併用療法の有効性の検討

塚本博丈, 藤枝浩司, 福島聡, 池田徳典, 宮下梓, 宮下梓, 久保陽介, 千住覚, 尹浩信, 押海裕之 …

日本がん免疫学会総会プログラム・抄録集, 21回 138-138, Jun, 2017
MHCを視点とした免疫異常・感染症治療戦略の新展開 HLA拘束性T細胞を活性化するがん抗原ペプチドワクチンの開発

西村泰治, 平山真敏, Sayem Mohammad Abu, 湯野晃, 冨田雄介, 今村悠哉, 千住覚, 塚本博丈, 井, 入江厚 …

MHC: Major Histocompatibility Complex, 23(2Suppl.) 59-59, Oct, 2016
CD4 T細胞を介した抗腫瘍免疫応答におけるIL-6/sIL-6Rの免疫抑制活性

塚本博丈, 藤枝浩司, 松村桂子, 千住覚, 西村泰治

日本癌学会総会記事, 75回 IS9-3, Oct, 2016
がんの進展制御における老化の役割加齢に伴うCD4陽性T細胞の機能不全と、それに伴う抗腫瘍免疫応答の低下

塚本博丈, 千住覚, 松村桂子, Swain Susan, 西村泰治

日本癌学会総会記事, 74回 S9-3, Oct, 2015
腎細胞癌患者における末梢血抑制性ミエロイド細胞の解析

元島崇信, 菰原義弘, 哈斯塔, 塚本博丈, 藤田貢, 西東洋一, 河野吉昭, 西村泰治, 竹屋元裕, 江藤正俊

日本癌学会総会記事, 74回 P-3234, Oct, 2015
腎細胞癌患者における末梢血抑制性ミエロイド細胞の解析

元島崇信, 菰原義弘, 哈斯塔, 塚本博丈, 西東洋一, 鹿瀬島裕, 河野吉昭, 西村泰治, 竹屋元裕, 江藤正俊

腎癌研究会会報, (45) 29-29, Jul, 2015
腎細胞癌患者における末梢血抑制性ミエロイド細胞の解析

元島崇信, 菰原義弘, 哈斯塔, 塚本博丈, 藤田貢, 西東洋一, 鹿瀬島裕, 河野吉昭, 西村泰治, 竹屋元裕 …

日本泌尿器科学会総会, 103回 594-594, Apr, 2015
悪性腫瘍と免疫系の相互作用担がん個体におけるIL-6シグナルを介したCD4+T細胞性腫瘍免疫の抑制(Interactions between malignant tumors and immune system Environmental attenuation of CD4+ T cell-mediated anti-tumor responses through IL-6 signaling)

西村泰治, 千住覚, スウェイン・スーザンエル, 塚本博丈

日本癌学会総会記事, 73回 S11-4, Sep, 2014
Age-associated increase of IL-6 dampens anti-tumor immune responses through attenuating Th1 differentiation of tumor-specific CD4 T cells

Hirotake Tsukamoto, Satoru Senju, Susan Swain, Yasuharu Nishimura

JOURNAL OF IMMUNOLOGY, 192, May, 2014
Myeloid-derived suppressor cells (MDSC)/IL-6-mediated attenuation of tumor-specific Th1 development

61(4) 428-435, 2014
腫瘍関連抗原のCD4+T細胞エピトープの同定に利用可能なHLA-DR4トランスジェニックマウスの樹立(Establishment of HLA-DR4 transgenic mice useful for identication of CD4+ T cell epitopes of tumor-associated antigens)

矢津田旬二, 入江厚, 湯野晃, 冨田雄介, 塚本博丈, 千住覚, 竹田直樹, 澁谷功, 十河真司, 藤木文博 …

日本癌学会総会記事, 72回 357-357, Oct, 2013
がん免疫の最前線(臨床的立場、橋渡し的立場、基礎研究) 担がん個体のミエロイド系抑制性細胞(MDSC)によるCD4+Th1細胞の分化抑制

西村泰治, 塚本博丈

日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 29回 56-56, Aug, 2013

Presentations

Exosomal miR192 regulates inflammatory response induced by Influenza whole vaccine

Tsukamoto Hirotake

Dec, 2019
Targeting of age-associated increased in IL-6 improves the responsiveness to cancer immunotherapies in old age

Tsukamoto Hirotake

Sep 27, 2019 Invited
Combined blockade of IL-6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment

Tsukamoto Hirotake

Dec, 2018
Combined blockade of IL-6 and PD-1/PD-L1 signals breaks mutual regulation of their immunosuppressive effects

Tsukamoto Hirotake

Sep 28, 2018 Invited
Combined blockade of IL-6 and PD-1/PD-L1 signals breaks mutual regulation of their immunosuppressive effects in tumor

Tsukamoto Hirotake

Dec, 2017
SASP factor IL-6-mediated dysfunction of CD4 T cells diminishes anti-tumor immunity in old age

Tsukamoto Hirotake

Nov 30, 2016 Invited
Immune-suppressive role of IL-6/sIL-6R signaling in CD4 T cell-mediated anti-tumor immunity

Tsukamoto Hirotake

Oct 8, 2016 Invited
Multifaceted dysfunction of CD4 T cells during aging process and their impact on antitumor immunity."

Tsukamoto Hirotake

Oct 8, 2015 Invited
IL-6-mediated environmental conditioning of defective Th1 differentiation dampens anti-tumor immune responses in old age

塚本博丈

日本免疫学会, 2014
Age-associated increase of IL-6 dampens anti-tumor immune responses through attenuating Th1 differentiation of tumor-specific CD4 T cells

American Association of Immunologists, 2014
Soluble IL-6 receptor diminishes the differentiation of tumor-specific Th1 cells to exacerbate tumor progression

日本免疫学会, 2013
担癌個体で増加する可溶性IL-6Rは、腫瘍特異的Th1細胞の分化抑制を介して腫瘍増大に寄与する

日本がん免疫学会, 2013
MDSC attenuate Th1 development of tumor-specific CD4+ T cells through IL-6 production

日本免疫学会総会, 2012
Gr-1+ MDSC attenuate development of tumor-specific Th1 cells through IL-6 production to promote tumor progression

第16回日本がん免疫学会総会, 2012

Teaching Experience

Professional Memberships

Works

Research Projects

development of therapeutic strategy for immune related adverse events by immune checkpoint inhivitor by focusing on B lymphocyte

Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Japan Society for the Promotion of Science, Apr, 2022 - Mar, 2025
免疫老化を基軸とした有害事象のマネジメント戦略とそれに基く新規がん免疫療法の開発

科学研究費助成事業基盤研究（B）, 独立行政法人日本学術振興会, Apr, 2021 - Mar, 2024

塚本博丈
加齢随伴炎症を標的としたがん免疫療法の効果増強戦略の開発

科学研究費補助金基盤研究（C）, Apr, 2018 - Mar, 2021

塚本博丈
Development of cancer immunotherapy using tumor-associated antigen-derived long peptides and liberation from immune suppression mediated trough IL-6 signaling

Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Japan Society for the Promotion of Science, Apr, 2015 - Mar, 2018

Nishimura Yasuharu, Eto Masatoshi, Nakayama Hideki, Tsukamoto Hirotake
CD4+T細胞を介した抗腫瘍免疫応答に対する可溶性IL-6受容体の影響の解析

科学研究費補助金基盤研究（C）, Apr, 2014 - Mar, 2016

塚本博丈
老齢個体におけるCD4陽性T細胞による抗腫瘍効果の抑制機構の解明

科学研究費補助金若手研究（B）, Apr, 2012 - Mar, 2014

塚本博丈
CD4陽性T細胞に対する骨髄系抑制性細胞の影響の解析

科学研究費補助金若手研究（B）, Apr, 2010 - Mar, 2012

塚本博丈

Profile Information

Research Interests

Research Areas

Research History

Education

Committee Memberships

Awards

Papers

Books and Other Publications

Misc.

Presentations

Teaching Experience

Professional Memberships

Works

Research Projects

Menu

Coauthors